OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Sunday morning. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and set a $4.25 price target on shares of OncoCyte in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $4.06.

OncoCyte Trading Down 1.3 %

OCX opened at $3.11 on Friday. The firm’s fifty day moving average is $3.13 and its two-hundred day moving average is $2.93. OncoCyte has a twelve month low of $2.08 and a twelve month high of $4.34.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The business had revenue of $0.10 million for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.